NIH Mix and Match Study Suggests mRNA COVID Vaccines May Offer Stronger Boost Than J&J

Though not designed to facilitate inter-group comparisons, a preprint study of heterologous and homologous boosting with the three US available COVID-19 vaccines indicate Johnson and Johnson primary vaccines may get greater protection from an mRNA booster.

NIH National Institue of Allergy and Infectious Diseases building
FDA's vaccine advisors will hear a presentation on mixing and matching COVID-19 booster shots from NIAID on 15 October. • Source: Alamy

People who got a booster dose of an mRNA COVID-19 vaccine following primary vaccination with Johnson & Johnson’s adenovirus COVID-19 vaccine generated a stronger antibody response than J&J patients boosted with another one of the sponsor’s adenovirus shots, new data from the US National Institutes of Health shows, throwing a possible wrench in J&J’s ability to capitalize on US boosters.

The US Food and Drug Administration’s Vaccine and Related Biological Products Advisory Committee is expected to vote on 15 October...

More from United States

More from North America

Elevidys Helps Sarepta To First US FDA Platform Technology Designation

 

Sarepta's rAAVrh74 vector, used in the marketed Duchenne muscular dystrophy gene therapy Elevidys and across the company's limb girdle muscular dystrophy pipeline, earned a platform designation as the lead LGMD candidate prepares for BLA filing.

Pink Sheet Podcast: The US and Ex-US Impact Of Most-Favored Nation Drug Pricing

Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.